To assess the viability of dynamic descriptors to capture differences between mutants in a potential mutant PCM model, a subset of 28 mutants from five of the GPCRs in our set was gathered: AA1R and AA2AR, muscarinic acetylcholine receptor 2 (ACM2), beta-2 adrenergic receptor (ADRB2), and CC chemokine receptor 5 (CCR5). The selection of mutations was done for the original set of 26 GPCRs when there was available mutagenesis data in GPCRdb (Table ), from which the point mutation's effect in bioactivity was projected for the five resulting receptors (Figure ). Additionally, five mutations on these GPCRs present in cancer patients from the Genomic Data Commons (GDC) database were included that also had mutagenesis data in GPCRdb: AA1R R291C 7.56 and R296C 8.51 , AA2AR H278N 7.42 , ACM2 V421L 7.33 , and ADRB2 V317A 7.43 . The cancer-related mutants, however, did not seem to have an effect in bioactivity given the limited amount of mutagenesis data available.